Volume 16, Number 1—January 2010
Research
Methicillin-Resistant and -Susceptible Staphylococcus aureus Infections in Dogs
Meredith C. Faires
, Michelle Traverse, Kathy C. Tater, David L. Pearl, and J. Scott Weese
, Michelle Traverse, Kathy C. Tater, David L. Pearl, and J. Scott Weese
Table 2
Univariable analysis of medical and surgical risk factors for MRSA versus MSSA infections in dogs, United States and Canada, 2001–2007*
| Variable† | MRSA, no. (%) dogs, n = 40 | MSSA, no. (%) dogs, n = 80 | Odds ratio (95% CI) | p value‡ |
|---|---|---|---|---|
| Received antimicrobial drugs | ||||
| No | 8 (20.0) | 30 (37.5) | Ref | |
| Yes | 26 (65.0) | 33 (41.3) | 3.84 (1.21–14.74) | 0.02 |
| Don’t know |
6 (15.0) |
17 (21.2) |
1.29 (0.28–5.65) |
0.75 |
| Received >2 antimicrobial drugs | ||||
| No | 25 (62.5) | 56 (70.0) | Ref | |
| Yes | 9 (22.5) | 7 (8.8) | 2.87 (0.81–11.49) | 0.08 |
| Don’t know |
6 (15.0) |
17 (21.2) |
0.79 (0.19–2.79) |
0.78 |
| Received an aminoglycoside | ||||
| No | 8 (20.0) | 30 (37.5) | Ref | |
| Yes | 1 (2.5) | 1 (1.3) | 5.71 (0.06–517.45) | 0.30 |
| Other classes§ | 25 (62.5) | 32 (40.0) | 3.80 (1.19–14.62) | 0.02 |
| Don’t know |
6 (15.0) |
17 (21.2) |
1.29 (0.28–5.62) |
0.75 |
| Received a β-lactam | ||||
| No | 8 (20.0) | 30 (37.5) | Ref | |
| Yes | 18 (45.0) | 25 (31.3) | 3.58 (1.04–14.79) | 0.04 |
| Other classes | 8 (20.0) | 8 (10.0) | 4.18 (0.96–20.88) | 0.04 |
| Don’t know |
6 (15.0) |
17 (21.2) |
1.31 (0.28–5.69) |
0.75 |
| Received chloramphenicol | ||||
| No | 8 (20.0) | 30 (37.5) | Ref | |
| Yes | 1 (2.5) | 2 (2.5) | 2.61 (0.04–65.5) | 1.00 |
| Other classes | 25 (62.5) | 31 (38.8) | 3.84 (1.21–14.74) | 0.02 |
| Don’t know |
6 (15) |
17 (21.2) |
1.29 (0.28–5.65) |
0.75 |
| Received a fluoroquinolone | ||||
| No | 8 (20.0) | 30 (37.5) | Ref | |
| Yes | 9 (22.5) | 7 (8.8) | 5.34 (1.24–27.38) | 0.01 |
| Other classes | 17 (42.5) | 26 (32.5) | 3.24 (0.94–13.2) | 0.06 |
| Don’t know |
6 (15.0) |
17 (21.2) |
1.31 (0.29–5.74) |
0.75 |
| Received a lincosamide | ||||
| No | 8 (20.0) | 30 (37.5) | Ref | |
| Yes | 2 (5.0) | 2 (2.5) | 4.43 (0.27–75.86) | 0.19 |
| Other classes | 24 (60.0) | 31 (38.8) | 3.77 (1.18–14.53) | 0.02 |
| Don’t know |
6 (15.0) |
17 (21.2) |
1.32 (0.29–5.73) |
0.75 |
| Received a nitroimidazole | ||||
| No | 8 (20.0) | 30 (37.5) | Ref | |
| Yes | 2 (5.0) | 0 | 7.18 (0.53–∞) | 0.07 |
| Other classes | 24 (60.0) | 33 (41.3) | 3.47 (1.08–13.33) | 0.03 |
| Don’t know |
6 (15.0) |
17 (21.2) |
1.38 (0.29–6.17) |
0.74 |
| Received a tetracycline | ||||
| No | 8 (20.0) | 30 (37.5) | Ref | |
| Yes | 2 (5.0) | 1 (1.3) | 6.63 (0.29–463.75) | 0.17 |
| Other classes | 24 (60.0) | 32 (40.0) | 3.54 (1.11–13.65) | 0.03 |
| Don’t know |
6 (15.0) |
17 (21.2) |
1.33 (0.29–5.88) |
0.74 |
| Hospitalized | ||||
| No | 16 (40.0) | 38 (47.5) | Ref | |
| Yes | 16 (40.0) | 25 (31.3) | 1.54 (0.58–4.14) | 0.37 |
| Don’t know |
8 (20.0) |
17 (21.3) |
1.17 (0.32–4.06) |
0.08 |
| Underwent surgical procedure | ||||
| No | 25 (62.5) | 46 (57.5) | Ref | |
| Yes | 10 (25.0) | 16 (20.0) | 1.07 (0.39–2.83) | 1.00 |
| Don’t know | 5 (12.5) | 18 (22.5) | 0.45 (0.09–1.68) | 0.26 |
*MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; CI, confidence interval; Ref, referent category. Dogs with MRSA (case-patients) and MSSA (controls) infections were matched for veterinary referral hospital and date of admission.
†Information obtained refers to the 90 days before admission to the veterinary referral hospital.
‡Score method for estimating p values does not assume a symmetrical distribution for discrete data. p<0.05 was considered significant.
§Refers to dogs given antimicrobial drugs from other drug classes.
Page created: March 31, 2011
Page updated: March 31, 2011
Page reviewed: March 31, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.